31 – 40 of 102
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2013
-
Mark
Consumption of fish and meats and risk of hepatocellular carcinoma: the European Prospective Investigation into Cancer and Nutrition (EPIC)
(
- Contribution to journal › Article
-
Mark
Dietary intake of acrylamide and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort
(
- Contribution to journal › Article
-
Mark
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer
(
- Contribution to journal › Scientific review
-
Mark
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
(
- Contribution to journal › Article
-
Mark
Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study
(
- Contribution to journal › Article
-
Mark
A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial.
(
- Contribution to journal › Article
-
Mark
Regarding the letter to the editor 'AIB1 and its significant role in tumor pathogenesis in systemic malignancies: beyond breast carcinomas' by Kapoor and Shailendra in Annals of Oncology.
(
- Contribution to journal › Letter
-
Mark
The role of AIB1 and PAX2 in primary breast cancer: validation of AIB1 as a negative prognostic factor.
(
- Contribution to journal › Article
-
Mark
A prospective, multicenter validation study of a prognostic index composed of S-phase fraction, progesterone receptor status, and tumour size predicts survival in node-negative breast cancer patients: NNBC, the node-negative breast cancer trial.
(
- Contribution to journal › Article
-
Mark
Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group.
(
- Contribution to journal › Article